ETHYNYL COMPOUNDS USEFUL FOR TREATMENT OF CNS DISORDERS
申请人:Green Luke
公开号:US20110152257A1
公开(公告)日:2011-06-23
The present invention relates to ethynyl compounds of formula
wherein X, Y, Z, and R
4
are as defined herein
or to a pharmaceutically acceptable salt or acid addition salt, to a racemic mixture, or to its corresponding enantiomer and/or optical isomer and/or stereoisomer thereof. Compounds of formula I are positive allosteric modulators (PAM) of the metabotropic glutamate receptor subtype 5 (mGluR5) and they are therefore useful for the treatment of diseases related to this receptor.
2-Oxo-1-Pyrrolidine Derivatives, Processes for Preparing Them and Their Uses
申请人:Kenda Benoît
公开号:US20090312333A1
公开(公告)日:2009-12-17
The present invention concerns 2-oxo-1-pyrrolidine derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals.
本发明涉及2-氧代-1-吡咯烷衍生物,其制备过程,包含它们的药物组合物以及它们作为药物的用途。
Ethynyl compounds useful for treatment of CNS disorders
申请人:Green Luke
公开号:US08586581B2
公开(公告)日:2013-11-19
The present invention relates to ethynyl compounds of formula
wherein X, Y, Z, and R4 are as defined herein
or to a pharmaceutically acceptable salt or acid addition salt, to a racemic mixture, or to its corresponding enantiomer and/or optical isomer and/or stereoisomer thereof. Compounds of formula I are positive allosteric modulators (PAM) of the metabotropic glutamate receptor subtype 5 (mGluR5) and they are therefore useful for the treatment of diseases related to this receptor.
ETHYNYL COMPOUNDS USEFUL FOR TREATMENT OF CNS DISORDER
申请人:Hoffmann-La Roche Inc.
公开号:US20140073638A1
公开(公告)日:2014-03-13
The present invention relates to ethynyl compounds of formula
wherein X, Y, Z, and R
4
are as defined herein
or to a pharmaceutically acceptable salt or acid addition salt, to a racemic mixture, or to its corresponding enantiomer and/or optical isomer and/or stereoisomer thereof. Compounds of formula I are positive allosteric modulators (PAM) of the metabotropic glutamate receptor subtype 5 (mGluR5) and they are therefore useful for the treatment of diseases related to this receptor.
The present invention concerns 2-oxo-1-pyrrolidine derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals.